Hong Kong Stock Movement: PEGBIO CO-B surged 20.08%, with active capital inflow attracting market attention

Hong Kong Stock Movement PEGBIO CO-B surged 20.08%, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks Ranked Among the Top in Industry Transaction Volume Sihuan Pharmaceutical rose 11.56%. Based on recent key news: On October 31, Sihuan Pharmaceutical's stock price rose over 11%, mainly due to Pfizer registering two global Phase III clinical trials for the PD-1/VEGF dual antibody on the Clinicaltrials.gov website. This news boosted market confidence in Sihuan Pharmaceutical's products, driving the stock price up. Source: Zhitong Finance On October 30, Pfizer introduced Sihuan Pharmaceutical's PD-1/VEGF dual antibody with a $1.25 billion upfront payment and $4.8 billion in milestone payments. This collaboration brought considerable financial support to Sihuan Pharmaceutical, further enhancing market expectations for its future development. Source: Zhitong Finance On October 29, Guojin Securities released a research report indicating that the development of innovative drugs requires sufficient financial support, and more funds are expected to be invested in innovative drug research and development in the future. This industry trend provides a favorable development environment for innovative drug companies like Sihuan Pharmaceutical. Source: Kechuangban Daily, financing scale in the innovative drug sector exceeds 1.23 trillion. Innovent Biologics rose 8.12%. Based on recent key news: On October 30, Innovent Biologics participated in the national medical insurance catalog negotiation, boosting market confidence. As one of the first companies to enter, Innovent Biologics is involved in the 2025 national medical insurance catalog negotiation, with market expectations that its products will gain broader market access, driving the stock price up. On October 30, Innovent Biologics released its third-quarter financial report, with revenue increasing by 40% year-on-year. The company's total product revenue in the third quarter exceeded RMB 3.3 billion, benefiting from the dual drivers of oncology and comprehensive pipelines, pushing the stock price up. On October 22, Innovent Biologics reached a cooperation agreement with Takeda Pharmaceutical, authorizing three products for overseas markets. Innovent Biologics will receive a $1.2 billion upfront payment and potential milestone payments, enhancing market confidence in its international strategy. The innovative drug sector continues to adjust, focusing on long-term value. Kangfang Biologics rose 2.43%. Based on recent key news: On October 30, Kangfang Biologics announced positive results from the HARMONi-A study. This study evaluated the novel bispecific antibody ivonescimab (PD-1/VEGF bispecific antibody), marking a significant breakthrough in the field. This result boosted investor confidence, driving the stock price up. On October 28, Kangfang Biologics' research update indicated key dates, including a launch date of November 14, 2024. These dates suggest potential investor interest and market entry timing, which may positively impact the stock price. The biotechnology sector in the Hong Kong market is active Stocks Ranked Among the Top by Market Capitalization in the Industry BeiGene rose 0.81%. Based on recent key news: On October 28, HSBC Research lowered BeiGene's third-quarter revenue forecast by 3% due to increased market competition and seasonal factors. Nevertheless, HSBC maintained a "Buy" rating, believing the company has long-term competitive advantages. On October 29, Guosen Securities pointed out that China's innovative drug industry has a long-term positive outlook, with significant growth in BD transactions. Although the difficulty of innovative drugs going overseas has increased, the domestic assets have a clear advantage of being "high quality and low price," and the adjustment in the innovative drug sector is basically in place. On October 28, data from Artery Network showed that the return rate for innovative drug License-out transactions is as high as 40%, indicating fierce market competition, and the difficulty of innovative drugs going overseas may increase in the future. The adjustment in the innovative drug sector is basically in place, and the long-term outlook is optimistic